Evaluation of lorlatinib efficacy of patients with EML4-ALK

Evaluation of lorlatinib efficacy of patients with EML4-ALK - Lorlatinib ctDNA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042617

Enrollment

150

Registered

2020-12-02

Start date

2019-02-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALK positive lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria 1. Patients aged 20 years or more in whom lorlatinib administration is scheduled under a diagnosis of non-small cell lung cancer with ALK gene translocation 2. Non-responders to alectinib therapy (or patients for whom it is discontinued due to the exacerbation of the primary disease or adverse events) 3. Patients who previously received treatment with cytotoxic anticancer drugs or untreated patients

Exclusion criteria

Exclusion criteria: 1. Patients from whom written informed consent regarding study participation was not obtained

Design outcomes

Primary

Measure	Time frame
Response rate (RECIST evaluated by the investigators)	—

Countries

Japan

Contacts

Public ContactYasushi Goto

National Cancer Center Hospital Thoracic Oncology

ygoto@ncc.go.jp0335422511

Outcome results